title: Antiandrogen withdrawal syndrome with nilutamide.
abstract: Antiandrogens are combined with medical or surgical castration to achieve total androgen blockade in metastatic prostate cancer. Discontinuation of antiandrogens at disease progression has been associated with prostate-specific antigen (PSA) decrease, symptom improvement, and occasionally objective tumor regression. Two cases of metastatic prostate cancer demonstrating decrease in PSA of 92% and 56% on discontinuation of nilutamide therapy are reported. Improvement in urinary symptoms, bone pain and, in one, disappearance of para-aortic lymphadenopathy paralleled the PSA decrease. The duration of the withdrawal response of 6 months was comparable to those reported with discontinuation of flutamide.
authors.affiliation: Division of Medical Oncology, Ottawa Regional Cancer Centre, Ontario, Canada.
authors.forename: S D
authors.initials: SD
authors.lastname: Huan
authors.forename: R G
authors.initials: RG
authors.lastname: Gerridzen
authors.forename: J C
authors.initials: JC
authors.lastname: Yau
authors.forename: D J
authors.initials: DJ
authors.lastname: Stewart
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists; D001859:Bone Neoplasms / Q000097:blood / Q000188:drug therapy / Q000556:secondary; D006801:Humans; D007093:Imidazoles; D048289:Imidazolidines; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D013375:Substance Withdrawal Syndrome
chemical_list: D000726:Androgen Antagonists; D007093:Imidazoles; D048289:Imidazolidines; C021277:nilutamide; D017430:Prostate-Specific Antigen